The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and early biologic effects of phase 1 PERIO-01 trial of pressure-enabled drug delivery (PEDD) of TLR9 agonist SD-101 and immune checkpoint inhibition (ICI) in uveal melanoma metastatic to the liver (MUM).
 
Kamaneh Montazeri
No Relationships to Disclose
 
Diwakar Davar
Honoraria - ACM Biolabs; Clinical Care Options (CCO); Gerson Lehrman Group; Medical Learning Group; Merck; Xilio Therapeutics
Consulting or Advisory Role - Checkmate Pharmaceuticals; Clinical Care Options; Finch Therapeutics; Gerson Lehrman Group; Xilio Therapeutics
Speakers' Bureau - Castle Biosciences
Research Funding - Arcus Biosciences; CellSight Technologies; Checkmate Pharmaceuticals; GlaxoSmithKline; Merck; Merck; Zucero Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Application No.: 63/124,231; Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy
 
Cara L. Haymaker
Stock and Other Ownership Interests - Briacell
Consulting or Advisory Role - Nanobiotix
Research Funding - BTG (Inst); Dragonfly Therapeutics (Inst); Idera (Inst); Iovance Biotherapeutics (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Patent Appl No. 62/977, 672 (Inst)
 
Rahul Sheth
Honoraria - TriSalus Life Sciences
Consulting or Advisory Role - TriSalus Life Sciences
 
Joshua Kuban
Consulting or Advisory Role - TriSalus Life Sciences
 
Joshua Weintraub
No Relationships to Disclose
 
Eric Wehrenberg-Klee
No Relationships to Disclose
 
Paula M. Novelli
No Relationships to Disclose
 
Carin F. Gonsalves
No Relationships to Disclose
 
Robert D. Adamo
No Relationships to Disclose
 
Anthony Lucci
No Relationships to Disclose
 
Salyna Meas
No Relationships to Disclose
 
Vanessa Nicole Sarli
No Relationships to Disclose
 
Victor Gerardo Prieto
Honoraria - Castle Biosciences
Consulting or Advisory Role - Merck
 
David A. Geller
No Relationships to Disclose
 
Marlana M. Orloff
Consulting or Advisory Role - Delcath Systems; IDEAYA Biosciences; Immunocore; TriSalus Life Sciences
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Delcath Systems (Inst); IDEAYA Biosciences (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Linnaeus Therapeutics (Inst); Plexxikon (Inst)
 
Richard D. Carvajal
Consulting or Advisory Role - Alkermes; Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Aura Biosciences; Bristol-Myers Squibb/Celgene; Bristol-Myers Squibb/Medarex (Inst); Castle Biosciences; Chimeron Bio; Corvus Pharmaceuticals (Inst); Delcath Systems; Eisai; Genzyme; Hengrui Pharmaceutical; IDEAYA Biosciences; IDEAYA Biosciences (Inst); Immunocore; InxMed; Iovance Biotherapeutics; Merck; Mirati Therapeutics (Inst); Novartis; Novartis (Inst); Oncosec; Pfizer (Inst); Pierre Fabre; Plexxikon (Inst); PureTech; Regeneron; Rgenix; Roche/Genentech (Inst); Roche/Genentech (Inst); Sorrento Therapeutics; TriSalus Life Sciences
Speakers' Bureau - Bristol-Myers Squibb/Medarex
Research Funding - Amgen (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
 
Sapna Pradyuman Patel
Honoraria - Delcath Systems; Emory University
Consulting or Advisory Role - Bristol Myers Squibb; Castle Biosciences; Delcath Systems; immatics; Immunocore; Novartis; Pfizer; Replimune; TriSalus Life Sciences
Research Funding - Bristol-Myers Squibb (Inst); Foghorn Therapeutics (Inst); InxMed (Inst); Lyvgen Biopharma (Inst); Novartis (Inst); Provectus (Inst); Seagen (Inst); Syntrix Biosystems (Inst); TriSalus Life Sciences (Inst)
Travel, Accommodations, Expenses - InxMed; TriSalus Life Sciences